Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): An open-label, randomised, phase 2 trial

Sagar Lonial*, Brendan M. Weiss, Saad Z. Usmani, Seema Singhal, Ajai Chari, Nizar J. Bahlis, Andrew Belch, Amrita Krishnan, Robert A. Vescio, Maria Victoria Mateos, Amitabha Mazumder, Robert Z. Orlowski, Heather J. Sutherland, Joan Bladé, Emma C. Scott, Albert Oriol, Jesus Berdeja, Mecide Gharibo, Don A. Stevens, Richard LeblancMichael Sebag, Natalie Callander, Andrzej Jakubowiak, Darrell White, Javier De La Rubia, Paul G. Richardson, Steen Lisby, Huaibao Feng, Clarissa M. Uhlar, Imran Khan, Tahamtan Ahmadi, Peter M. Voorhees

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

527 Scopus citations

Fingerprint

Dive into the research topics of 'Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): An open-label, randomised, phase 2 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences